MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

Search

REGENXBIO Inc

Closed

SectorHealthcare

7.05 4.75

Overview

Share price change

24h

Current

Min

6.55

Max

7.23

Key metrics

By Trading Economics

Income

8.4M

-51M

Sales

-3M

21M

EPS

-1.01

Profit margin

-241.284

Employees

353

EBITDA

17M

-38M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+391.12% upside

Dividends

By Dow Jones

Next Earnings

7 May 2025

Market Stats

By TradingEconomics

Market Cap

94M

392M

Previous open

2.3

Previous close

7.05

News Sentiment

By Acuity

34%

66%

103 / 386 Healthcare

Technical Score

By Trading Central

Confidence

Strong Bearish Evidence

REGENXBIO Inc Chart

Past performance is not a reliable indicator of future results.

Related News

1 Apr 2025, 23:15 UTC

Major Market Movers

Hims & Hers Adds Eli Lilly's Zepbound in Expansion of Weight-Loss Offerings -- 2nd Update

1 Apr 2025, 23:46 UTC

Market Talk

Market Grapples With Valuing Goodman's Data Centers -- Market Talk

1 Apr 2025, 23:44 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

1 Apr 2025, 23:44 UTC

Market Talk

Global Equities Roundup: Market Talk

1 Apr 2025, 23:44 UTC

Market Talk

Nikkei May Trade Rangebound Amid U.S. Tariff Uncertainty -- Market Talk

1 Apr 2025, 23:43 UTC

Market Talk

Gold Steady, Underpinned by Signs of Chinese Buying Activity -- Market Talk

1 Apr 2025, 23:11 UTC

Top News

Risk Off Trade Is Getting Crowded. It's More Worry Than Panic. -- Barrons.com

1 Apr 2025, 23:02 UTC

Market Talk

New Zealand May Be Measuring Stick for Trade-War Fallout -- Market Talk

1 Apr 2025, 22:31 UTC

Top News

Wilbur Ross Has Thoughts on Trump's Tariffs -- Barrons.com

1 Apr 2025, 22:26 UTC

Market Talk

RBA's Focus on What It Doesn't Know Boosts May Cut Odds -- Market Talk

1 Apr 2025, 21:47 UTC

Top News

Wilbur Ross Has Thoughts on Trump's Tariffs -- Barrons.com

1 Apr 2025, 21:32 UTC

Top News

Hooters' Bankruptcy Is the Latest Sign of Trouble for Restaurants -- Barrons.com

1 Apr 2025, 21:06 UTC

Market Talk

Mexican Remittances See Slow Start to the Year -- Market Talk

1 Apr 2025, 21:00 UTC

Market Talk

ESG Roundup: Market Talk

1 Apr 2025, 20:50 UTC

Market Talk
Acquisitions, Mergers, Takeovers

Financial Services Roundup: Market Talk

1 Apr 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

1 Apr 2025, 20:47 UTC

Top News

Boeing Stock Drops. Why Lower 737 MAX Production Report Wasn't Quite Right. -- Barrons.com

1 Apr 2025, 20:47 UTC

Top News

BYD Will Beat Tesla Two Ways This Quarter -- Barrons.com

1 Apr 2025, 20:20 UTC

Top News

Trump's 'Liberation Day' Tariffs Loom; Treasury Yields Fall -- WSJ

1 Apr 2025, 20:15 UTC

Acquisitions, Mergers, Takeovers

Eaton Completes Acquisition Of Fibrebond >ETN

1 Apr 2025, 20:11 UTC

Market Talk

Altria Stock Seen Overvalued Amid Steep Volume Losses -- Market Talk

1 Apr 2025, 20:07 UTC

Acquisitions, Mergers, Takeovers

Johnson & Johnson Intends to Complete Its Acquisition of Intra-Cellular Therapies on or Around April 2 >JNJ

1 Apr 2025, 20:00 UTC

Top News

Americans Are Worried About Tariffs. Consumer Stocks Could Take a Hit. -- Barrons.com

1 Apr 2025, 19:46 UTC

Top News

Visa, American Express Bidding to Win Apple Credit-Card Network, Sources Say -- WSJ

1 Apr 2025, 19:43 UTC

Market Talk

Oil Rally Loses Momentum Ahead of U.S. Tariff Plans -- Market Talk

1 Apr 2025, 19:17 UTC

Top News

Meta's Head of AI Research to Resign Amid Computing Push -- Update

1 Apr 2025, 19:13 UTC

Market Talk

U.S. Natural Gas Futures Give Back Gains -- Market Talk

1 Apr 2025, 19:03 UTC

Market Talk

Don't Rush Into Trade Talks With U.S., Canadian Experts Advise Lawmakers -- Market Talk

1 Apr 2025, 19:00 UTC

Market Talk

Gold Slips Ahead of Tariff Day -- Market Talk

1 Apr 2025, 18:54 UTC

Market Talk

Mexican Manufacturing PMIs Reflect Tariff Threats -- Market Talk

Peer Comparison

Price change

REGENXBIO Inc Forecast

Price Target

By TipRanks

391.12% upside

12 Months Forecast

Average 33.2 USD  391.12%

High 50 USD

Low 14 USD

Based on 11 Wall Street analysts offering 12 month price targets forREGENXBIO Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

11 ratings

10

Buy

1

Hold

0

Sell

Technical Score

By Trading Central

N/A / 8.36Support & Resistance

Short Term

Strong Bearish Evidence

Intermediate Term

Weak Bearish Evidence

Long Term

No Evidence

Sentiment

By Acuity

103 / 386 Healthcare

News Sentiment

Bullish Evidence

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About REGENXBIO Inc

REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy. It also develops RGX-121 for the treatment of mucopolysaccharidosis type II that is in Phase III clinical trial; RGX-111 for treating mucopolysaccharidosis type I; RGX-181 for the treatment of late infantile neuronal ceroid lipofuscinosis type II; and RGX-381 to treat the ocular manifestations of CLN2 disease. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland.